SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-212519
Filing Date
2022-08-04
Accepted
2022-08-04 16:11:37
Documents
14
Period of Report
2022-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d362778d8k.htm   iXBRL 8-K 26110
2 EX-99.1 d362778dex991.htm EX-99.1 89291
6 GRAPHIC g362778g0804090109555.jpg GRAPHIC 4760
  Complete submission text file 0001193125-22-212519.txt   253961

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20220804.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20220804_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20220804_pre.xml EX-101.PRE 11263
8 EXTRACTED XBRL INSTANCE DOCUMENT d362778d8k_htm.xml XML 3424
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 221136673
SIC: 2836 Biological Products, (No Diagnostic Substances)